|
|
|
European Pharmaceutical Contractor
|
PharmaCluster Finland is a unique mixture of science and business. The Cluster was created within the framework of the National Centre of Expertise Programme. Its aim is to facilitate development of the new pharma network in Finland. Cluster members represent established industries, start-up companies, research and educational units and also venture capital funds. All the key players in the field are members of the Cluster. This broad base offers good opportunities to influence decision-makers in specific development activities relating to the pharmaceutical industry in Finland.
Finland - Key Strengths:
One of the most important factors in the success story of Finnish high tech is the high level of investment devoted to R&D. In 2002 more than three per cent of the total GDP was invested in future research activities
According to a United Nations Development Programme (UNDP) report released in 2001, Finland is the most advanced country in creating and using technology
The International Institute for Management Development (IMD) ranked Finland second in overall industry competitiveness in 2002
According to the World Economic Forum (WEF), Finland is ranked first in current competitiveness, growth competitiveness and economic creativity. In innovation capacity, Finland is ranked second and in technology third
Finland has more than 140 biotech companies making it sixth in the European ranking
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
DIA Annual EuroMeeting
26-28 March 2012, Copenhagen, Denmark
The EuroMeeting attracts more than 3,000 professionals from over 50 countries. It brings together professionals from the biopharmaceutical industry, contract service organisations, clinical research, regulatory agencies, health ministries, patients’ organisations and universities. This convergence affords attendees the opportunity to network with professional colleagues from around the world.
More info >> |
|
 |
News and Press Releases |
 |
APTAR PHARMA’S PRESERVATIVE-FREE MULTIDOSE DISPENSER OSD CHOSEN FOR THE FIRST TIME FOR AN EYE CARE PRODUCT
Aptar Pharma’s innovative and patented preservative-free multidose Ophthalmic Squeeze Dispenser (OSD) has found its first application for the treatment of dry eye with the launch of VISMED® MULTI. Aptar Pharma has worked closely with the Swiss-German based Eye Care specialist TRB Chemedica for improving patient safety, achieving dosing accuracy and maintaining product stability on the ophthalmic spray device.
More info >> |
|
|
